Press release 📈 Stocks 🌍 United States

MetaVia Presents Phase 1 Clinical Trial Data for DA-1726 at Symposium

MetaVia Inc. shares Phase 1 clinical trial data for its novel dual oxyntomodulin candidate DA-1726, advancing its pipeline for the treatment of cardiometabolic diseases.

📅 October 28, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: MTVA → 3/10 (55% confidence).

📊 Affected Assets (1)

MTVA

Neutral 🤖 55%

📅 Short-term 🌍 US · Explicit

MetaVia announced an oral presentation of Phase 1 clinical trial data for DA-1726 at a symposium, a clinical milestone with no efficacy results disclosed.

🧭 Full analysis of these assets

🎯 Key Takeaways

MetaVia presented Phase 1 data for DA-1726 at a medical symposium.
The drug candidate targets cardiometabolic diseases as a dual oxyntomodulin.
The presentation marks a significant clinical milestone for the Cambridge-based biotech.

📝 Executive Summary

MetaVia Inc. announced an oral presentation of Phase 1 clinical trial data for its cardiometabolic drug candidate, DA-1726. The company shared preliminary findings at a recent medical symposium, marking a key development milestone for the clinical-stage biotechnology firm.

❓ FAQ

What is the primary focus of MetaVia's DA-1726 candidate?

DA-1726 is a novel dual oxyntomodulin being developed by MetaVia to treat cardiometabolic diseases.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article